Diabetes mellitus remission in a cat with pituitary-dependent hyperadrenocorticism after trilostane treatment

Muschner, A C; Varela, F V; Hazuchova, K; Niessen, S J M

Abstract

An 8-year-old male neutered Persian cat was presented with polyuria, polydipsia, polyphagia and muscle weakness associated with a 7 month history of diabetes mellitus (DM). The cat had initially been treated with neutral protamine Hagedorn (NPH) insulin 2 U q12h, followed by porcine lente insulin 2 U q12h and, most recently, 3 U glargine insulin q12h, without improvement of clinical signs. The cat also suffered from concurrent symmetrical bilateral alopecia of thorax and forelimbs, abdominal distension and lethargy. Hyperadrenocorticism (HAC), specifically pituitary-dependent HAC, was suspected and confirmed through abdominal ultrasonography demonstrating bilateral adrenal enlargement, and a low-dose dexamethasone suppression test using 0.1 mg/kg dexamethasone intravenously. Trilostane treatment (initially 10 mg/cat PO q24h then increased to 10 mg/cat PO q12h) was started and insulin sensitivity gradually improved, ultimately leading to diabetic remission after an increased in trilostane dose to 13mg/cat PO q12h, 14 months after the DM diagnosis and 7 months after the initiation of trilostane therapy.

Citation

Muschner, A. C., Varela, F. V., Hazuchova, K., & Niessen, S. J. M. (2018). Diabetes mellitus remission in a cat with pituitary-dependent hyperadrenocorticism after trilostane treatment. Journal of Feline Medicine and Surgery Open Reports, 4(1), https://doi.org/10.1177/2055116918767708

• Journal Article Type: Other
• Acceptance Date: Feb 27, 2018
• Publication Date: Apr 16, 2018
• Deposit Date: May 1, 2018
• Publicly Available Date: Nov 21, 2020
• Journal: Journal of Feline Medicine and Surgery Open Reports
• Publisher: SAGE Publications
• Peer Reviewed: Peer Reviewed
• Volume: 4
• Issue: 1
• DOI: https://doi.org/10.1177/2055116918767708
• Public URL: https://rvc-repository.worktribe.com/output/1387663